SARS-CoV-2 main protease targeting potent fluorescent inhibitors: Repurposing thioxanthones

Gönül S Batibay1, Eyüp Metin1,2

  • 1Department of Chemistry, Faculty of Arts and Sciences, Yıldız Technical University, İstanbul, Turkiye.

PubMed

Insights

Researchers explored thioxanthone molecules as potential inhibitors for the SARS-CoV-2 main protease. A specific thioxanthone derivative with a para-oxygen-di-acetic acid group showed the most promising inhibitory effects and stability.

Area of Science:

  • Medicinal Chemistry
  • Computational Biology
  • Drug Discovery

Background:

  • The global impact of coronavirus disease (COVID-19) necessitates urgent development of effective treatments.
  • Understanding SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) mechanisms and identifying therapeutic targets are crucial.

Purpose of the Study:

  • To investigate the potential of thioxanthone-based molecules as inhibitors of the SARS-CoV-2 main protease.
  • To evaluate the binding affinity and stability of candidate molecules using computational methods.

Main Methods:

  • Computational screening of diverse thioxanthone derivatives.
  • Molecular docking and adsorption, distribution, metabolism, excretion, and toxicity (ADMET) analyses.
  • Molecular dynamics simulations of promising candidates against the SARS-CoV-2 main protease.

Main Results:

  • Thioxanthone molecules exhibited varying degrees of intermolecular interactions with the SARS-CoV-2 main protease.
  • A thioxanthone derivative featuring a para-oxygen-di-acetic acid functional group demonstrated superior inhibitory potential.
  • This lead compound exhibited enhanced stability and a higher number of intermolecular interactions during molecular dynamics simulations.

Conclusions:

  • Thioxanthone-based compounds represent a promising class of molecules for targeting the SARS-CoV-2 main protease.
  • The para-oxygen-di-acetic acid functionalized thioxanthone is a strong candidate for further development as an antiviral agent against COVID-19.